Endocrinologist Deserts; U.S. Obesity Declines; New Obesity Definition Coming Soon

Almost 70% of U.S. counties are “endocrinologist deserts,” meaning they lack a single practicing endocrinologist, according to GoodRx.

In a phase IV trial of patients with Cushing’s syndrome and a baseline HbA1c over 7.5%, those who received mifepristone (Korlym) had a 1.32% greater decrease in HbA1c than placebo by week 24, Corcept Therapeutics said.

Americans’ average body mass index and obesity prevalence declined in 2023, the first drop in more than a decade, cross-sectional data suggested. (JAMA Health Forum)

In the 15-week phase III THRIVE-2 trial, investigational veligrotug significantly improved proptosis and diplopia in people with chronic thyroid eye disease, said Viridian Therapeutics.

The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity will soon unveil a new evidence-based definition of obesity that’s endorsed by 75 medical organizations.

Cheaper vials of tirzepatide (Zepbound) will be available on the direct-to-consumer app Ro through a partnership with Eli Lilly. (CNBC)

The American Diabetes Association released its 2025 Standards of Care in Diabetes; updates include recommendations for continuous glucose monitors and caution about compounded GLP-1 drugs. (Diabetes Care)

Early life exposure to the endocrine-disrupting chemicals polychlorinated biphenyls was linked to some neurobehavioral problems in a rat model. (Journal of the Endocrine Society)

A lawsuit accused major food companies of allegedly causing chronic disease by designing ultraprocessed foods to be addictive to children. (CNN)

Dexcom said its prescription-free glucose biosensor Stelo now has an integrated AI platform to help improve metabolic health.

Some people are microdosing semaglutide (Ozempic, Wegovy) and other weight-loss medications. Does it work? (New York Times)

Please enable JavaScript to view the

comments powered by Disqus.